Simulating the Hallmarks of Cancer

Cancer can be viewed as the loss of cooperative cell behaviors that normally facilitate multicellularity, including the formation of tissues and organs. Hanahan and Weinberg describe the phenotypic differences between healthy and cancerous cells in an article titled The Hallmarks of Cancer (Cell, 100, 5770, 2000). Here the authors propose six phenotypic changes at the cellular level as the essential hallmarks of cancer. They investigate the dynamics and interactions of these hallmarks in a model known as CancerSim. They describe how CancerSim implements the hallmarks in an agent-based simulation which can help test the hypotheses put forth by Hanahan and Weinberg. Experiments with CancerSim are described that study the interactions of cell phenotype alterations, and in particular, the likely sequences of precancerous mutations, known as pathways. The experiments show that sequencing is an important factor in tumorigenesis, as some mutations have preconditionsthey are selectively advantageous only in combination with other mutations. CancerSim enables a modeler to study the dynamics of a developing tumor and simulate how progression can be altered by tuning model parameters.

[1]  J. Folkman Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[2]  R. Rubin The war on cancer. , 1996, U.S. news & world report.

[3]  K Sikora,et al.  Developing a global strategy for cancer. , 1999, European journal of cancer.

[4]  John S. Lowengrub,et al.  A New Ghost Cell/Level Set Method for Moving Boundary Problems: Application to Tumor Growth , 2008, J. Sci. Comput..

[5]  Ami Radunskaya,et al.  A delay differential equation model for tumor growth , 2003, Journal of mathematical biology.

[6]  K. Loeb,et al.  Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Petrelli,et al.  The onset and extent of genomic instability in sporadic colorectal tumor progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  James H. Brown,et al.  A general model for ontogenetic growth , 2001, Nature.

[9]  Memorial Sloan-Kettering,et al.  Theoretical Concepts and the Emerging Role of Taxanes in Adjuvant Therapy , 2001 .

[10]  M. Sporn The war on cancer , 1996, The Lancet.

[11]  E. Epel,et al.  Accelerated telomere shortening in response to life stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  O RAJKA,et al.  [TUMOR IMMUNOLOGY]. , 1963, Orvosi hetilap.

[13]  Stephanie Forrest,et al.  Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[15]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[16]  A. Bouchez,et al.  The response of Jupiter's magnetosphere to an outburst on Io. , 1997, Science.

[17]  L. Buss,et al.  The evolution of individuality , 1987 .

[18]  Stephanie Forrest,et al.  Exploring the Relationship between Neutral and Selective Mutations in Cancer , 2000, Artificial Life.

[19]  J Kuikka Allometric scaling laws in biology. , 1997, Science.

[20]  Evan T Keller,et al.  Detection and isolation of circulating tumor cells in urologic cancers: a review. , 2004, Neoplasia.

[21]  J. Lowengrub,et al.  Nonlinear simulation of the effect of microenvironment on tumor growth. , 2007, Journal of theoretical biology.

[22]  S. Spencer,et al.  An ordinary differential equation model for the multistep transformation to cancer. , 2004, Journal of theoretical biology.

[23]  W. Bodmer,et al.  How many mutations in a cancer? , 2002, The American journal of pathology.

[24]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[25]  C A Beuchat Allometric scaling laws in biology. , 1997, Science.

[26]  L. Hayflick THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.

[27]  Marina Ziche,et al.  Development of new drugs in angiogenesis. , 2004, Current drug targets.

[28]  Fariba Behbod,et al.  Will cancer stem cells provide new therapeutic targets? , 2005, Carcinogenesis.

[29]  A. Prokop,et al.  Nanovehicular intracellular delivery systems. , 2008, Journal of pharmaceutical sciences.

[30]  M. Blagosklonny,et al.  How carcinogens (or telomere dysfunction) induce genetic instability: associated‐selection model , 2001, FEBS letters.

[31]  R. Medema,et al.  The role of p21ras in receptor tyrosine kinase signaling. , 1993, Critical reviews in oncogenesis.

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  David S Wishart,et al.  Computational systems biology in drug discovery and development: methods and applications. , 2007, Drug discovery today.

[34]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.